Akero Therapeutics Inc

Akero Therapeutics — Investor Presentation (September 2019)

19 slides from Akero Therapeutics's investor presentation, Sep 6, 2019

  1. Slide 1: Safe Harbor

    Safe Harbor This presentation has been prepared by Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securitie

  2. Slide 2: Building Value on a Strong Foundation

    AKERO Building Value on a Strong Foundation 3 AKR-001, Fc-FGF21 fusion protein, licensed from Amgen 3-4 day half-life for QW dosing Robust effects on lipoproteins and markers of insulin sensitivity in 83 T2D patients in two Phase 1 trials Well tolerated Currently in Phase 2a FGF analogs observed to

  3. Slide 3: Leadership

    4 LEADERSHIP Andrew Cheng, MD, PhD President & CEO 19 years at Gilead Chief Medical Officer & HIV Division Head Major role in 11 NDA/MAA approvals Jonathan Young, PhD, JD Founder, EVP & COO Over 15 years in biotechnology product development, law and regulatory policy General Counsel and VP Policy, B

  4. Slide 4: Completed Upsized IPO; Strong Financial Position

    5 COMPLETED UPSIZED IPO June 20, 2019 $16 Price upsized IPO at top of marketing range ~$106M Raised in aggregate gross proceeds Q2 EARNINGS UPDATE June 30, 2019 $7.6M Q2 operating expenses ~$163M Cash and cash equivalents FUNDED THROUGH 2022 Phase 2b STRONG FINANCIAL POSITION Projected completion by

  5. Slide 5: NASH: A Serious and Debilitating Condition

    6 NASH A SERIOUS AND DEBILITATING CONDITION An estimated 17 million Americans have NASH The US NASH patient population is expected to grow over 50% to 27 million by 2030 A GROWING HEALTH EPIDEMIC The number of NASH patients with advanced-stage fibrosis and cirrhosis is predicted to grow to 8 million

  6. Slide 6: FGF21 Targets All Core Stages of NASH Pathogenesis

    7 FGF21 TARGETS ALL CORE STAGES OF NASH PATHOGENESIS Excessive Caloric Burdening of Liver Excessive Liver Fat, Fat Oxidation Hepatocyte cell stress, injury, death Inflammation Fibrosis Improve insulin sensitivity Redirect calories away from liver without weight gain Reduce all three sources of liver

  7. Slide 7: Understanding the Sources of Liver Fat and Relevant FGF Receptors

    UNDERSTANDING THE SOURCES OF LIVER FAT AND RELEVANT FGF RECEPTORS 8 Source of Liver Fat FGF Receptor FGF21 Activity Lipolysis FGFR1c De Novo Lipogenesis FGFR2c FGFR3c Lambert, JE et al. (2014) Gastroenterology 146(3): 726-35 Acting on both hepatic and peripheral sources of liver fat is key to optimi

  8. Slide 8: Impact of Balanced FGFR Agonism on Fat Reduction

    Impact of Balanced fgfr Agonism on Fat Reduction Liver fat reduction of 67% (MRI-PDFF) largest reported among all candidates that we know to be targeting FGFRs Balanced potency at FGFR1c, 2c, 3c appears to drive liver fat reduction FGFR4 appears unnecessary for glucose sensitivity & liver fat reduct

  9. Slide 9: Potential for Improved Liver Histology Within Weeks

    Potential for Improved Liver Histology Within 12 Weeks aldafermin (NGM282) appeared to improve biopsy-based measures in NASH patients after 12 weeks Underscores the capacity of -Klotho-dependent FGFR agonism to improve NASH and reverse fibrosis May open up opportunity to accelerate path to registrat

  10. Slide 10: AKR-001 Engineering Potentially Optimal for NASH Efficacy

    AKR-001 Engineering Potentially Optimal for NASH Efficacy Key attributes 11 Stanislaus , S et al. (2017) Endocrinology 158(5): 1314-27; Lee, S et al. (2018) Nature 553: 501-505; Kharitonenkov, A et al. (2007) Endocrinology 148(2)774-781 Amgen-designed Fc-FGF21, Point mutations Increases half-life fr

  11. Slide 11: AKR-001 Reproduced Balanced In Vitro Potency

    AKR-001 Reproduced Balanced In Vitro Potency 12 Pharmacology of other FGF21 analogs has not been disclosed for individual receptors AKR-001, rhFGF21, and rhFGF19 Activation of FGFR-Dependent Intracellular Signaling in L6 Cells Stanislaus, S et al. (2017) Endocrinology 158(5):1314-1327

  12. Slide 12: Promising Data from Phase 1 Clinical Trials

    Improved Lipoproteins Weight Neutral 13 PROMISING DATA FROM PHASE 1 CLINICAL TRIALS And support AKR-001’s potential, in NASH patients, to be METABOLIC Redirect calories away from the liver Reduce liver fat Reduce hepatocellular stress and cell death ANTI-FIBROTIC Suppress inflammation Reverse fibros

  13. Slide 13: AKR-001 Improved Lipoprotein Profile

    14 Percent Change From Baseline, Placebo, 21 mg QW and 70 mg QW a Day 25; b Day 29 ** = p<0.01; *** = p<0.001 AKR-001’s significant improvements in lipoproteins and reduction in adipose lipolysis are consistent with effective agonism of FGFR2c and 3c in the liver and FGFR1c in adipose tissue AKR-001

  14. Slide 14: AKR-001 Improved Insulin Sensitivity

    AKR-001’s significant improvement in insulin sensitivity is consistent with effective FGFR1c agonism Percent Change From Baseline, Placebo, 21 mg QW and 70 mg QW a Day 25; b Day 29 * = p<0.05; ** = p<0.01; *** = p<0.001 15 AKR-001 IMPROVED INSULIN SENSITIVITY -29% -54% +107% -14% -47% Insulina Gluco

  15. Slide 15: AKR-001 Improved Lipoproteins Rapidly and Durably

    AKR-001 Improved Lipoproteins Rapidly and Durably 16 AKR-001 70 mg QW effects on lipoproteins in Phase 1b clinical trial -8,200 -5,700 -3,200 -700 1,800 4,300 6,800 -70% -50% -30% -10% 10% 30% 50% 1 7 14 21 28 35 42 49 56 Serum AKR - 001 (ng/mL) Change from Baseline Study Day HDL-C LDL-C Triglycerid

  16. Slide 16: Phase 2a Trial: The BALANCED Study

    17 PHASE 2A TRIAL: THE BALANCED STUDY NUMBER OF SUBJECTS About 80 PRIMARY ENDPOINT Absolute change from baseline in hepatic fat fraction (MRI-PDFF) at week 12 A Phase 2a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the safety, tolerability and efficacy of

  17. Slide 17: Milestones Delivered and Projected

    Milestones DELIVERED Milestones PROJECTED JUN 8 Q1 Q2 $45.5M Series B MRI-PDFF Read-out May 24 MAR 13 JUN 20 JUL 2 1st Patient Dosed IND Active ~$106M Upsized IPO Amgen License $45M Series A DEC 5 Liver Biopsy Read-out 2018 2019 2020 18

  18. Slide 18: Thank You

    THANK YOU. CORPORATE PRESENTATION

  19. Slide 19: Thank You

    ak=ro THANK YOU.

Akero Therapeutics — Investor Presentation (September 2019) on 6ix